Brokerages Set Pediatrix Medical Group, Inc. (NYSE:MD) PT at $22.50

Pediatrix Medical Group, Inc. (NYSE:MD) has earned an average recommendation of “Hold” from the six ratings firms that are covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $23.3333.

Several equities research analysts have recently weighed in on the stock. Truist Financial increased their target price on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. UBS Group boosted their price target on Pediatrix Medical Group from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Wednesday, June 24th. Mizuho set a $24.00 price objective on Pediatrix Medical Group in a research report on Friday, May 8th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $27.00 target price on shares of Pediatrix Medical Group in a research note on Monday, April 20th.

Insider Buying and Selling at Pediatrix Medical Group

In related news, Director Shirley A. Weis sold 36,028 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total transaction of $855,665.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of large investors have recently bought and sold shares of the company. Wasatch Advisors LP lifted its stake in shares of Pediatrix Medical Group by 21.9% in the 2nd quarter. Wasatch Advisors LP now owns 2,498,884 shares of the company’s stock worth $63,297,000 after acquiring an additional 448,360 shares during the period. Pacer Advisors Inc. increased its stake in shares of Pediatrix Medical Group by 2.5% during the first quarter. Pacer Advisors Inc. now owns 506,757 shares of the company’s stock worth $10,840,000 after acquiring an additional 12,376 shares during the period. Amundi raised its holdings in Pediatrix Medical Group by 8.3% during the first quarter. Amundi now owns 15,744 shares of the company’s stock worth $337,000 after purchasing an additional 1,209 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Pediatrix Medical Group by 77.7% during the first quarter. EverSource Wealth Advisors LLC now owns 2,515 shares of the company’s stock worth $54,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Quantinno Capital Management LP raised its holdings in Pediatrix Medical Group by 23.4% during the first quarter. Quantinno Capital Management LP now owns 22,928 shares of the company’s stock worth $490,000 after purchasing an additional 4,343 shares in the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Down 0.9%

Shares of NYSE:MD opened at $26.11 on Friday. The stock has a market cap of $2.14 billion, a P/E ratio of 12.67 and a beta of 0.66. The firm has a fifty day moving average price of $23.92 and a 200 day moving average price of $22.19. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.33 and a quick ratio of 1.33. Pediatrix Medical Group has a 1-year low of $11.84 and a 1-year high of $27.94.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. The company had revenue of $476.20 million for the quarter, compared to the consensus estimate of $465.83 million. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. Pediatrix Medical Group’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period last year, the firm posted $0.33 EPS. Sell-side analysts predict that Pediatrix Medical Group will post 2.1 EPS for the current year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.